PRESS RELEASE published on 06/10/2026 at 07:30, 2 months 27 days ago Inside Information / Other news releases Sensorion achieves key regulatory milestones for SENS-601 addressing GJB2-related hearing loss and discontinues SENS-501. Fast Track procedure granted by ANSM in France. Clinical trials planned in Canada and U.S. IND submission targeted by 2026 Clinical Trials Gene Therapy Sensorion Regulatory Milestones GJB2-related Hearing Loss
PRESS RELEASE published on 06/10/2026 at 07:30, 2 months 27 days ago Informations privilégiées / Autres communiqués Sensorion franchit des étapes réglementaires clés pour SENS-601 dans la perte auditive liée au gène GJB2 et le sélectionne comme principal candidat-médicament en thérapie génique Thérapie Génique Sensorion Perte Auditive SENS-601 Gène GJB2
BRIEF published on 05/18/2026 at 07:35, 3 months 20 days ago Sensorion Appoints Fred Chereau as CEO Biotechnology CEO Appointment Gene Therapy Sensorion Fred Chereau
BRIEF published on 05/18/2026 at 07:35, 3 months 20 days ago Fred Chereau appointed Managing Director of Sensorion Gene Therapy General Management Hearing Loss Sensory Fred Chereau
BRIEF published on 05/18/2026 at 07:35, 3 months 20 days ago Fred Chereau nommé Directeur Général de Sensorion Direction Générale Thérapie Génique Sensorion Fred Chereau Pertes D'audition
BRIEF published on 05/18/2026 at 07:35, 3 months 20 days ago Sensorion nomme Fred Chereau au poste de PDG Biotechnologie Thérapie Génique Nomination Du PDG Sensorion Fred Chereau
PRESS RELEASE published on 05/18/2026 at 07:30, 3 months 20 days ago Informations privilégiées / Autres communiqués Sensorion nomme Fred Chereau au poste de Directeur Général, apportant son expertise en biotechnologie et thérapie génique. Amit Munshi continue en tant que Président du Conseil d'Administration Biotechnologie Thérapie Génique Sensorion Amit Munshi Fred Chereau
PRESS RELEASE published on 05/18/2026 at 07:30, 3 months 20 days ago Inside Information / Other news releases Sensorion appoints Fred Chereau as Chief Executive Officer, bringing extensive leadership experience in gene therapy and rare diseases. Amit Munshi continues as Chairman of the Board Gene Therapy Chief Executive Officer Rare Diseases Sensorion Fred Chereau
BRIEF published on 05/13/2026 at 07:35, 3 months 25 days ago Results of the Sensorion General Meeting Biotechnology General Assembly Resolutions Adopted Hearing Loss Sensory
BRIEF published on 05/13/2026 at 07:35, 3 months 25 days ago Résultats de l'Assemblée Générale de Sensorion Biotechnologie Assemblée Générale Résolutions Adoptées Sensorion Pertes Auditives
Published on 09/05/2026 at 04:05, 2 days 21 hours ago Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 2 hours ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 2 hours ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 3 hours ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 3 days 11 hours ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/07/2026 at 19:19, 6 hours 21 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Sales and Adjusted EBIT in Q2 2026/27 above prior-year level – FY outlook maintained
Published on 09/07/2026 at 19:00, 6 hours 40 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 août 2026 au 4 septembre 2026
Published on 09/07/2026 at 18:42, 6 hours 58 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/07/2026 at 18:00, 7 hours 40 minutes ago E-PANGO: e-Pango organise un webinaire avec ses actionnaires
Published on 09/07/2026 at 17:45, 7 hours 55 minutes ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 09/07/2026 at 19:00, 6 hours 40 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 6 hours 40 minutes ago Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 7 hours 35 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
Published on 09/07/2026 at 18:05, 7 hours 35 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/08/2026
